u/NovosLabs

If a gene helps survival earlier in life but raises mortality later on, should we still think of it as a “good” longevity gene?

TL;DR
This large mouse study suggests ageing genetics is dynamic: many variants influence mortality differently depending on age, sex, and body size, rather than simply making lifespan longer or shorter.

Quick Takeaways
• This paper mapped age-specific genetic effects on lifespan and mortality across the full lives of a very large mouse cohort.
• The evidence comes from 6,438 genetically diverse mice, with repeated actuarial mapping across 72 age-truncated survivorship groups.
• The main takeaway is that many loci are stage-specific, and a substantial subset reverses direction with age, often with strong sex differences.

Context
A lot of ageing research treats lifespan like a single final score: one number measured at death. That is useful, but it can flatten the biology. Two animals can die at the same age for very different reasons. One may be relatively resilient early and fragile later. Another may show the opposite pattern. If you only look at total lifespan, you miss the timing.

That is exactly the problem this paper tries to solve. Instead of asking which variants are associated with longer life overall, the authors ask when different variants affect mortality risk, and whether those effects differ between males and females. To do that, they used the largest mouse ageing dataset of its kind from the NIA Interventions Testing Program and applied an actuarial mapping approach across progressively older survivorship groups.

The design is unusually strong. The study began with 6,438 pubescent mice and followed them until death, with the last death at 1,456 days. The authors then analysed 72 nested survivorship groups, starting with mice alive at day 42 and ending with the 559 mice that survived past 1,100 days. That let them ask whether a locus mattered early, in midlife, late, or across much of life.

A more realistic way to map ageing genes
Using this actuarial approach, the authors identified 29 Vita loci that influence lifespan and mortality patterns. Average effect sizes were meaningful rather than trivial: the loci shifted life expectancy by about 36 ± 12 days on average, and some genotype contrasts were larger at specific loci and ages. Importantly, those effects were often not stable across the lifespan. Some loci acted mainly early, others mainly in midlife, others only very late, and a minority showed more durable effects across broader age windows. A substantial subset actually reversed direction with age: a genotype could look beneficial in one age window and harmful in another.

That is a major conceptual point. The paper pushes back against the idea that “longevity genes” are fixed, timeless switches that are either good or bad. Many appear to behave more like moving trade-offs inside a changing system. The authors explicitly connect several of these patterns to antagonistic pleiotropy, where a variant may lower mortality before 400–600 days but raise it later.

The sex differences were not subtle
One of the clearest findings is that males and females do not share the same ageing map. Early in life, female mice had a major survival advantage: at the starting truncation age, mean lifespan was 887 ± 175 days in females versus 806 ± 210 days in males, an 81-day gap. That difference later narrowed because male mortality was much heavier between about 215 and 410 days.

Genetically, these differences were widespread. The paper reports 14 Vita loci with strong genotype-by-sex interactions. Some loci even had opposite effects in males and females, and some also reversed with age. The chromosome 2 region containing Vita2b and Vita2c is one of the clearest examples: genotypes that were advantageous in females could be disadvantageous in males, and the direction of effect in males could change over time. The authors make the point very clearly that pooling the sexes without modelling interaction terms can generate misleading signals.

There was also a male-specific X-chromosome signal, called VitaXa, which the authors suggest may reflect recessive effects revealed by male hemizygosity. More broadly, genetic effects on lifespan appeared more pronounced in males early on, whereas females showed stronger and more stable epistatic variance across reproductive life.

Body size was not just a confounder
The second major contribution of the paper is the mapping of 30 Soma loci, which modulate the relationship between body mass and life expectancy. This is important because the study was not simply asking whether bigger mice live shorter lives. It was asking whether genetics changes how strongly body size predicts lifespan.

The broad pattern fits earlier mouse work but adds much more detail. Body mass measured early in life correlated negatively with later lifespan in both sexes, but much more strongly in males. At around 183 days, the rank correlation was about −0.28 in males and −0.11 in females. The authors translate that into a striking estimate: at the reproductive peak, males lost about 14.3 days of life per extra gram, versus 3.7 days in females. Later in life, that negative relationship weakened and could even flip positive, especially for body mass measured around 730 days.

Genetically, 19 Soma loci strengthened the early-life pattern in which larger young mice had higher mortality, while 11 Soma loci were linked to the opposite pattern later in life, where larger old mice did better. Effect sizes ranged from about 2 to 29 days per gram depending on locus and genotype.

That makes the body-size story much more interesting than “bigger is bad.” Early growth may trade off against later maintenance, but in older animals low body mass may also reflect frailty or declining resilience.

What this means for ageing theory
The discussion explicitly connects the findings to three classic evolutionary theories of ageing. Late-acting loci fit mutation accumulation, because variants with harmful effects after reproduction are less exposed to selection. Reversing loci fit antagonistic pleiotropy, because variants that help earlier can hurt later. And the early Soma loci fit disposable soma logic, where investment in growth or reproduction appears to trade off against later maintenance.

That said, this is still a mouse genetics paper, not a final answer for humans. The intervals are often broad, many mechanisms remain unresolved, and some variance may reflect site effects, social stress, or other unmodelled factors. The authors themselves note that the loci explain only part of the story, especially late in life when other sources of variance become more important.

Still, the paper argues strongly against simple, timeless “good gene versus bad gene” narratives in ageing biology. Ageing genes do not seem to act as permanent levers with fixed direction. They look conditional, context-dependent, often sex-dependent, and sometimes in conflict across life stages.

Discussion Prompt
What do you think matters more for future longevity research: finding genes with small stable effects across life, or understanding the genes that flip from beneficial to harmful depending on age and sex?

Informational only, not medical advice.

Reference: https://www.nature.com/articles/s41586-026-10407-9

• TL;DR

A new Nature Aging review argues that visceral fat is not inherently harmful; its risk depends on whether it becomes inflamed, dysfunctional, and metabolically pathogenic.

• Quick Takeaways

• This review asks whether visceral adipose tissue, or VAT, is merely a marker of poor metabolic health or a context-dependent driver of metabolic decline and aging. • The authors pull together animal experiments, human imaging studies, Mendelian randomization analyses, and early intervention data, including mesenteric fat removal studies. • The main message is more nuanced than “belly fat bad”: VAT amount matters, but VAT quality and biological state may matter more.

• Context

For years, visceral fat has had a very simple public reputation: it is the “bad fat,” the one around the organs, the one linked to diabetes, fatty liver disease, cardiovascular disease, frailty, and shorter lifespan. That view is not exactly wrong, but this review argues that it is incomplete.

The paper is very clear that VAT is not automatically pathological. Under physiological conditions, it has real roles in structural support, local metabolic support, immune regulation, and endocrine signaling. The problem begins when VAT transitions into a pathogenic state. The diagram on page 3 illustrates this shift visually, showing how healthy VAT can become pathogenic through lipid overflow, local hypoxia, inflammatory remodeling, endocrine disruption, senescence, and aging-related loss of adipose plasticity.

That framing matters because it changes the question. Instead of asking only how much visceral fat is present, the review pushes us to ask what state the tissue is in.

• What the evidence actually says

One strength of the paper is that it does not rely on one evidence type. It moves across observational human studies, Mendelian randomization, rodents, primates, and early human interventions. On the observational side, the association between more visceral fat and worse outcomes is strong: VAT tracks more closely than BMI or total fat mass with insulin resistance, type 2 diabetes, cardiovascular disease, liver disease, frailty, and mortality. The review cites imaging-based studies showing that each standard-deviation increase in VAT area was associated with a substantially higher mortality risk, independent of sex and subcutaneous fat.

But observational evidence always leaves open the same question: is VAT causing harm, or just tagging along with other harmful processes?

That is where the interventional animal work matters. In rodents, removing visceral fat improved metabolic health, while transplanting certain visceral depots worsened it. One rat study found that VAT removal extended both mean and maximum lifespan by about 10%, despite similar body weight and total fat mass afterward. In mice, epididymal VAT removal protected against diet-induced dyslipidemia, steatosis, and insulin resistance, and in aged mice VAT removal also reduced inflammation and lessened brain injury after stroke.

The primate and early human intervention data are especially interesting because they move beyond a pure mouse story. Traditional omentectomy in humans has largely failed to improve insulin sensitivity, but the review argues that this may reflect the wrong depot being targeted. Mesenteric VAT may matter more than omental VAT. In baboons, removal of most visible mesenteric VAT increased glucose disposal rates dramatically within six weeks. A first-in-human pilot study then removed mesenteric VAT in people with poorly controlled type 2 diabetes and reported improvements in glycemic control, hepatic insulin sensitivity, liver fat, and beta-cell function over 6–12 months. These are small studies, but they are difficult to dismiss.

• Why VAT quality may matter more than VAT quantity

This is probably the most useful idea in the paper. The review repeatedly argues that VAT quantity is an imperfect predictor of risk and that what matters most is whether the depot has undergone harmful remodeling. That is stated explicitly in the text and illustrated clearly in the page 3 schematic.

The biological model is intuitive. Chronic positive energy balance, limited ability of subcutaneous fat to expand, and reduced preadipocyte differentiation push VAT adipocytes to enlarge. That hypertrophy may outstrip blood supply, creating local hypoxia, secretory dysfunction, immune-cell recruitment, and inflammatory remodeling. Aging adds another layer through hormonal shifts, chronic low-grade inflammation, stromal-vascular dysfunction, and senescent-cell accumulation. The result is not just “more fat,” but a tissue that behaves differently.

The review even includes counterexamples showing that visceral fat is not always harmful. Ames dwarf mice have increased VAT but improved metabolic health and longer lifespan, and removing their VAT worsens insulin sensitivity. Transplanting their VAT into normal mice improves glucose homeostasis. That is a strong reminder that tissue behavior matters at least as much as tissue location.

• How pathogenic VAT may accelerate aging

The review organizes the mechanistic story into four main mediators, summarized visually on page 4: inflammation and cellular senescence, adipokines, exosomes, and metabolites.

Inflammation is the most familiar. VAT often shows a more inflammatory profile than SAT, and aging seems to intensify that shift. The review also points to senescent cells and the SASP as possible amplifiers, while noting that simple senescent-cell counts are not always uniquely higher in VAT than SAT. The important difference may be the nature of the inflammatory signaling, not just the number of senescent cells.

The adipokine section focuses on the classic pattern of higher leptin and lower adiponectin in pathogenic VAT. Chronic hyperleptinemia may promote leptin resistance and inflammation, while low adiponectin undermines insulin sensitivity and healthy lipid handling. The authors even discuss partial leptin reduction and adiponectin receptor agonism as future strategies.

The exosome section is one of the more forward-looking parts of the paper. The review summarizes evidence that VAT-derived exosomes can carry pathogenic miRNAs that affect blood vessels, macrophages, and possibly brain function. In obese mice, VAT exosomes promoted atherosclerosis more strongly than SAT exosomes, and one study linked VAT-derived exosomal miR-9-3p to hippocampal dysfunction and memory problems. In humans with type 2 diabetes, higher miR-9-3p in VAT exosomes and serum correlated with cognitive impairment.

Finally, the metabolite section revisits the portal hypothesis: omental and mesenteric VAT drain directly to the liver, sending FFAs, inflammatory mediators, and lipotoxic signals such as ceramides and diacylglycerols straight into hepatic metabolism. The review also discusses altered MAGs, FAHFAs, BMP, and BCAA-related metabolism as additional candidate mediators.

• What should we do with this?

The practical section is one of the best parts of the review because it avoids oversimplifying the problem. Established strategies like caloric restriction, exercise, bariatric surgery, and GLP-1 receptor agonists can reduce VAT burden and improve metabolic health, but the review makes clear that they do not all work just by “melting bad fat.” The page 7 figure captures this well, laying out both established and emerging approaches to either reduce VAT volume or neutralize its pathogenic biology.

The emerging strategies are especially interesting: senolytics, partial leptin reduction, adiponectin receptor agonists, ceramide synthesis inhibition, exosome-based therapies, mesenteric VAT lipectomy, microbiome modulation, thermogenesis, and gene therapy. Some are speculative, some are surprisingly concrete, and several are still far from clinical use. But together they reinforce the core message: future interventions may focus less on total body fat and more on preventing VAT from becoming biologically pathogenic in the first place.

• Bottom line

My main takeaway is that this review makes visceral fat feel less like a static enemy and more like a tissue-state problem. That is a more complicated story, but probably a more useful one. VAT does seem capable of contributing causally to metabolic dysfunction and aging, but not in a simple “all visceral fat is toxic” way. Context matters. Depot biology matters. Aging itself matters. And the shift from healthy VAT to pathogenic VAT may be the real event worth targeting.

Discussion Prompt

If VAT becomes dangerous mainly when it turns inflammatory, senescent, and endocrinologically dysfunctional, should longevity medicine focus less on “losing belly fat” and more on changing the biology of the depot itself?

Informational only.

Reference: https://www.nature.com/articles/s43587-026-01076-4

What would you think of a strategy that tries to support cartilage, bone, and muscle together instead of treating each tissue as a separate aging problem?

• TL;DR

In aged mice, a combo of NMN plus apigenin raised NAD+ availability, reduced senescence-related markers, improved musculoskeletal tissue phenotypes, and was partly linked to SIRT3 and the gut-derived metabolite phytosphingosine.

• Quick Takeaways

• This paper tested whether preserving the NAD+ pool with two compounds at once could counter age-related decline across cartilage, bone, and muscle.

• The evidence spans cell culture, naturally aged 20-month-old mice, Sirt3 knockout mice, fecal microbiota transfer, and stool metabolomics.

• The results are interesting, but this remains preclinical work in mice and cell lines, not evidence that the same regimen safely regenerates human musculoskeletal tissue.

• Context

Aging rarely damages just one part of the musculoskeletal system. Cartilage degenerates, bones lose density, and skeletal muscle shrinks and weakens. In real life, those problems interact: less muscle means less joint support, joint degeneration reduces movement, and lower loading can further weaken bone. That is why a strategy aimed at the cartilage-bone-muscle axis is conceptually appealing.

This paper starts from a familiar aging theme: declining NAD+ availability. The authors argue that aged musculoskeletal tissues show dysregulated NAD+ metabolism, more senescence, and poorer regenerative capacity. Their proposed solution is a “double-pronged” regimen: increase NAD+ biosynthesis with nicotinamide mononucleotide (NMN) while reducing NAD+ consumption with apigenin (API), described here as a CD38 inhibitor. They call the combination N+A. The scheme on page 3 lays out this logic visually, linking N+A to preserved NAD+, downstream SIRT3 activity, reduced senescence, musculoskeletal regeneration, and a possible gut-metabolite contribution through PHS.

• Why the NAD+ angle is attractive here

The first question the study asks is whether aging musculoskeletal cells actually look NAD+-depleted. According to the authors, yes. Using public single-cell transcriptomic datasets, they found age-related changes in NAD+-related genes across muscle fibers, muscle stem cells, chondrocytes, and osteoblasts. In cell models of aging-like stress, including TBHP-induced oxidative stress, doxorubicin-induced DNA damage, and replicative senescence, the authors observed more SA-β-gal positivity, lower ATP, lower NAD+, and a lower NAD+/NADH ratio. Figure 1 on pages 4–5 summarizes that foundation across the ATDC5, MC3T3, and C2C12 cell systems.

That matters because lineage differentiation is metabolically demanding. If precursor cells are low on energy and trapped in a senescence-like state, they become less capable of differentiating into functional chondrocytes, osteoblasts, or myocytes.

Then comes the intervention. NMN alone helped. Apigenin alone helped. But the combination usually worked better. In other words, the paper does not show that NMN was inactive on its own; it shows that the dual strategy of increasing NAD+ supply while reducing NAD+ consumption generally produced the strongest effect. Around pages 5 to 7, the paper shows that N+A raised NAD+ and the NAD+/NADH ratio more than either compound alone, reduced SA-β-gal staining, lowered p53, p21, and p16-related signals, and improved mitochondrial membrane potential and respiration-linked measures. In short, the cells looked less senescent and more metabolically competent.

• What changed in cartilage, bone, and muscle?

The next question is whether the cells actually regained differentiation-related function, not just cleaner biomarkers.

For cartilage, N+A increased glycosaminoglycans, aggrecan-related matrix output, type II collagen, and SOX9-linked signaling in the chondrogenic system. For bone, it increased alkaline phosphatase activity, calcium deposition, and osteogenic markers including OPG and osteocalcin. For muscle, it promoted myotube formation and increased markers like MHC, MyoD1, and myogenin. Figure 3 on page 7 is the clearest visual summary of this tri-lineage differentiation story.

The in vivo section is where the paper becomes more compelling. The authors orally treated naturally aged 20-month-old mice and then examined cartilage, bone, and muscle phenotypes. Figure 4 on page 8 shows reduced cartilage degeneration with lower OARSI scores, better cartilage structure, improved bone micro-CT parameters including trabecular number and bone volume fraction, and improved muscle histology with larger myofiber area and less fibrosis. They also report functional improvements including paw grip strength, more normalized gait parameters, and higher activity in the open-field test.

That is probably the strongest part of the paper. Many aging studies show molecular changes without obvious organism-level outputs. Here, at least in aged mice, the authors present both tissue-level and functional readouts.

• How much depends on SIRT3 and the gut?

The paper does not stop at “NAD+ went up.” It asks whether SIRT3, a mitochondrial deacetylase, is part of the mechanism. In Sirt3−/− aged mice, the N+A regimen still raised circulating NAD+ measures, but many downstream protective effects on cartilage, bone, muscle, and physical function were blunted. That is a useful nuance: SIRT3 was not required for NAD+ to rise, but it appears to contribute to a meaningful part of the downstream phenotype. The paper also reports reduced mitochondrial protein acetylation after N+A, which fits the SIRT3 story. Figure 5 on pages 9–10 illustrates this attenuation clearly.

Then the paper moves into the gut. Because the regimen was given orally, the authors examined intestinal tissue, 16S profiles, FMT, and stool metabolomics. N+A-treated aged mice showed improved intestinal-barrier-related markers, increased microbial alpha diversity, and shifts in taxa including higher Ruminococcus and Coriobacteriaceae_UCG-002. FMT from N+A-treated aged donors improved senescence-related outcomes in cartilage, bone, and muscle of recipient aged mice, broadly resembling the effect of FMT from young donors. Figures 6 and 7 support this microbiota-plus-metabolite section.

Metabolomics then highlighted sphingolipid-related changes, and the authors focused on phytosphingosine (PHS) as a candidate mediator. They report that oral PHS itself improved cartilage, bone, and muscle phenotypes in aged mice and reduced p53/p21 and p16-associated senescence signals. They also found positive correlations between PHS and Coriobacteriaceae_UCG-002 and Ruminococcus. That does not prove those microbes directly generate PHS, but it supports the idea that microbiome remodeling may contribute to the broader phenotype.

• What to make of it

This is a strong mechanistic mouse paper with very broad scope. It links preserved NAD+ availability, reduced senescence-related signaling, mitochondrial deacetylation through SIRT3, tri-lineage differentiation, microbiome shifts, and a candidate gut-derived metabolite into one integrated story. That is ambitious, and the paper pulls it off better than many do.

But it also creates several places where readers could overinterpret the findings. The work relies heavily on mouse models and immortalized cell lines. Group sizes are modest in key experiments, often n=3–5 in cell work and n=5 in many in vivo quantifications. The paper shows many significant shifts, but not every result is presented in a way that makes practical magnitude easy to judge. And because this is a combination intervention, it remains difficult to cleanly separate the contribution of NMN, apigenin, gut remodeling, and their interaction. Most importantly, none of this shows that people should expect joint, bone, or muscle regeneration from supplement use.

Still, the broader concept is worth watching: future mobility-focused aging interventions may need to target the cartilage-bone-muscle axis rather than one tissue at a time.

Informational only.

Reference: https://onlinelibrary.wiley.com/doi/epdf/10.1111/acel.70468

If a drug is supposed to improve aging biology, what should we make of it when it does not seem to add to exercise, and may even reduce some early gains in older adults?

TL;DR
In this small randomized trial, weekly sirolimus did not boost exercise gains in older adults and may have modestly attenuated them while adding more side effects.

Quick Takeaways
• This study tested whether once-weekly sirolimus could improve the effects of a 13-week exercise program in sedentary adults aged 65–85.
• The evidence came from a randomized, double-blind, placebo-controlled trial with functional outcomes like chair-stands, walking distance, grip strength, and safety labs.
• The main signal was not enhancement but possible attenuation: placebo generally did better, and sirolimus came with more minor adverse events and one serious infection.

Context

Rapamycin and sirolimus have become popular in longevity discussions for a reason. In animal models, mTOR inhibition can extend lifespan and improve several age-related traits. That has led to an appealing idea: maybe a carefully timed dose could suppress some chronically elevated mTOR signaling associated with aging, while still allowing exercise to trigger the anabolic response needed for muscle adaptation. The authors call this the “cycling hypothesis.”

The catch is that muscle is one of the places where timing matters most. mTOR is not an abstract aging pathway in skeletal muscle; it is deeply involved in protein synthesis and training adaptation. That is why this trial is useful. It did not ask whether sirolimus does anything biologically. It asked whether older adults can take it in a way that preserves or enhances the functional gains usually seen when sedentary people start exercising.

What the trial actually did

The trial randomized 40 sedentary, community-dwelling adults aged 65–85, with a mean age of 72.2 years, to either sirolimus 6 mg once weekly or matched placebo for 13 weeks. Both groups followed the same home-based exercise program three times per week: repeated 30-second chair-stands for lower-body resistance work and a progressively harder exercycle protocol for endurance. The study drug was taken about 24 hours after the last weekly exercise session to try to avoid the peak post-exercise anabolic window.

The main outcome was change in the 30-second chair-stand test, a practical marker of lower-body function and independence in older adults. Secondary outcomes included 6-minute walk distance, grip strength, SF-36 quality-of-life scores, CRP, and several epigenetic age metrics. The authors were clear that this was an exploratory trial, designed more to estimate effect sizes and safety than to deliver a definitive final answer.

The main result: no boost, and possibly some interference

Both groups improved over 13 weeks, which is exactly what you would expect when sedentary older adults begin exercising regularly. The more important question was whether sirolimus improved those gains. It did not. In the primary intention-to-treat analysis, the adjusted mean difference in chair-stand repetitions was −2.13 in the sirolimus group versus placebo, with a 95% CI of −4.61 to 0.34 and p = 0.089. That did not reach conventional statistical significance, but the direction still favored placebo.

The prespecified sensitivity analyses made the pattern harder to ignore. In the complete-case analysis, the difference was −2.46 repetitions and reached significance. In the per-protocol analysis, which focused on participants who adhered better to both medication and exercise, the difference widened to −3.44 repetitions, again favoring placebo. That is the part of the paper that makes the “possible blunting” interpretation feel more credible than random noise.

The chart on page 8 visually supports that read: both groups improved, but the placebo group’s mean chair-stand gains look larger, and the individual response plots show more upward movement in placebo than in rapamycin.

Secondary outcomes also leaned toward placebo

The secondary functional outcomes told a similar story, even if none were statistically significant. The adjusted difference in 6-minute walk distance was −4.87 m, and the adjusted difference in grip strength was −1.19 kg, both favoring placebo. SF-36 physical and mental summary scores also showed small non-significant differences favoring placebo. The epigenetic age measures were mixed and did not show a clear short-term advantage for sirolimus over 13 weeks.

So the most defensible reading is not that weekly sirolimus “wrecked” exercise adaptation. It is that, in this setting, it did not help and may have modestly attenuated some of the early functional gains older adults usually get from training. That is also very close to the paper’s own conclusion.

Why this might have happened

The authors’ proposed explanation is plausible. Although dosing was timed about 24 hours after the final weekly exercise session, sirolimus has a terminal half-life of roughly 62 hours. That means biologically active concentrations likely persisted well into the following training week. If that happened, mTORC1 may still have been partially inhibited during later exercise-recovery windows, when muscle needed that pathway for adaptation.

That matters because it suggests timing is not a side detail. It may be central. The “cycling hypothesis” only works if the catabolic/autophagic phase and the anabolic/training-adaptation phase are separated cleanly enough in real life. This schedule may simply not have created that separation.

Safety: manageable, but not trivial

Adverse events were common in both groups, with 85% of participants in each arm reporting at least one. But the total event burden was higher with sirolimus: 99 total events versus 63 with placebo. Drug-related events were also more frequent in the sirolimus group. Most were mild, such as headache, fatigue, and upper respiratory symptoms, but there was one serious adverse event: a participant in the sirolimus arm developed community-acquired pneumonia and withdrew from the trial. The authors explicitly say a causal role cannot be excluded.

Lab changes were also directionally relevant. LDL cholesterol and HbA1c rose modestly in the sirolimus arm, alongside a few other statistically significant but clinically modest lab shifts. None of that proves a major safety problem from this dose in all settings, but it does make the intervention look less casually benign than some online longevity discussions imply.

Bottom line

This study does not settle the rapamycin question. It narrows it. In sedentary older adults starting a 13-week home-based exercise program, 6 mg of sirolimus once weekly did not enhance short-term functional gains and may have slightly reduced them, while also increasing the burden of adverse events.

The practical takeaway is not that rapamycin is useless. It is that longevity pharmacology may not be plug-and-play with exercise biology. If sirolimus eventually has a role here, it may require a lower dose, a longer interdose interval, a longer trial, or a different population entirely. The authors themselves point in that direction, suggesting future trials with lower or less frequent dosing and longer follow-up.

Informational only

Reference: https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.70274

What would it take to switch a therapeutic gene on in a defined region, for a defined amount of time, without drugs or implanted devices?

TL;DR
This preclinical study describes an electromagnetic-field-responsive gene switch that remotely and reversibly activated genes in vivo, with intriguing aging, Alzheimer’s-modeling, and serotonergic-restoration results in mice.

Quick Takeaways
• The paper introduces an EMF-inducible promoter element, Ei, that allowed researchers to switch genes on using a defined EMF condition.
• Evidence came from cell experiments, CRISPR screening, reporter mice, progeria and aged mice, an inducible Alzheimer’s disease model, and a serotonin-deficient depression model.
• The results are notable, but they remain preclinical, largely in mice, and the exact sensing mechanism plus large-animal translation remain unresolved.

Context
One of the hardest problems in gene therapy is not just delivering a gene, but controlling when and where it turns on. Drug-inducible systems can work, but they depend on molecules that may have off-target effects. Light-based systems are elegant, but light penetrates tissue poorly. Heat, ultrasound, and electrical approaches each solve part of the problem, but often trade off spatial precision, reversibility, or practicality in living animals. That is the backdrop for this paper.

The authors built a gene switch that responds to a specific EMF condition: 2.0 mT at 60 Hz. They identified a naturally EMF-responsive promoter region upstream of Lgr4, reduced it to a 450-base-pair element, and used that sequence as the core switch, which they call Ei. One major longevity-related application is partial reprogramming, where timing matters enormously because too little expression may do very little, while too much risks pushing cells toward unsafe dedifferentiation.

How the switch works, and why that matters

The mechanistic side is one of the paper’s strongest features. The team did not stop at showing that EMF changes transcription. They performed a genome-wide CRISPR-Cas9 knockout screen in reporter cells and identified Cyb5b as a required mediator for EMF responsiveness. When Cyb5b was knocked out, the switch stopped responding; when it was reintroduced, the response returned. That gives the study a stronger mechanistic footing than many earlier EMF-related claims.

They also argue that the switch is not simply responding to generic calcium entry. Instead, EMF induced a distinctive pattern of rhythmic calcium oscillations, and only that oscillatory pattern activated the switch. Conventional calcium-raising stimuli did not reproduce the same transcriptional output. Downstream, Sp7 appears to bind the Ei element during EMF exposure, linking the calcium dynamics to transcriptional activation.

That matters because bio-orthogonality is the whole point of a useful control system. If a switch can be activated by random cellular stress, it is not a very good switch. The authors also report low basal leakage when EMF is absent, reversibility after withdrawal, and little sign that simply inducing Lgr4 under physiological conditions triggers canonical Wnt or stress pathways unless additional ligand is supplied. In wild-type mice exposed to the study’s EMF condition for six months, the authors did not detect obvious neurological, renal, hepatic, hematologic, metabolic, or broad transcriptomic toxicity under their testing conditions. That is encouraging, though still far from proving safety in humans.

The longevity angle: partial reprogramming with a remote timer

For longevity readers, the headline application is the Ei-OSK system, where Oct4, Sox2, and Klf4 are placed under EMF control. The group first optimized the schedule, and that part is extremely important. Continuous or overly long induction was harmful: EMF exposure for 4 or more consecutive days increased mortality and caused significant weight loss. A cyclic schedule of 3 days ON / 4 days OFF was tolerated much better and became the working regimen. In other words, the paper reinforces a central lesson of reprogramming biology: timing and dose are critical.

They then tested this in two aging contexts. In progeroid mice, treatment began at 3 months and ran for 90 days. In naturally aged mice, treatment began at 20 months and ran for 120 days. According to the figure legend on page 10, the progeria survival experiment used groups ranging from n=10 to n=12, while the aged-mouse survival/body-weight experiment used n=7 to n=8. In the progeroid model, the reported outcomes included improved appearance, reduced spinal curvature, less body-weight decline, and longer median and maximal lifespan under the cyclic Ei-OSK regimen. Histology and molecular readouts also suggested restoration of several aging-associated features, including vascular structure, age-linked histone marks, and lower p16INK4a.

This is the part that will attract the most attention, but it is also where caution matters most. The study shows reversal of several aging-associated phenotypes, not proof that aging as a whole has been broadly reversed. It also does not provide the kind of standard wild-type lifespan-extension evidence people would want for a sweeping geroscience claim. Still, as a control platform for partial reprogramming, the result is notable: the system appears precise enough to capture some upside while avoiding obvious reprogramming catastrophe under the selected schedule.

A clever Alzheimer’s model, not an Alzheimer’s cure

The authors also used the same platform to build an inducible Alzheimer’s disease model. They engineered mice carrying mutant humanized APP variants under Ei control, then activated expression with localized EMF. The point here is subtle but important: many AD models express pathology-driving genes from early life, which mixes developmental effects with aging effects. This system lets researchers switch mutant APP on later, including in aged brains, and ask what happens in an already old neural environment.

After EMF exposure, the mice showed increased APP β-cleavage products, higher soluble and insoluble Aβ40 and Aβ42, plaque deposition, neuroinflammatory changes, and cognitive deficits. Critically, aged inducible mice developed worse pathology than young inducible mice, including a higher Aβ42:Aβ40 ratio, greater plaque burden, more microglial and astrocyte accumulation, and worse performance on the Y-maze, contextual fear conditioning, and Morris water maze. According to the figure legends on pages 11–12, several of those behavioral comparisons used n=6 per group, while some biochemical outputs were smaller.

That does not prove amyloid is the full explanation for sporadic AD. But it does provide a useful platform for separating what mutant APP does from what an aged brain does when that pathology is introduced later in life.

Why cyclic timing outperformed continuous expression in the serotonin experiment

The third application may be the most conceptually elegant. In a Tph2-R439H knock-in mouse model with deficient serotonin synthesis, the group used a faster second-generation switch, sEi, to restore Tph2 expression in the dorsal raphe. In fibroblasts, Tph2 induction appeared by about 6 hours, peaked around 12 hours, and returned toward baseline after withdrawal. In vivo, the researchers compared cyclic EMF (12 h ON / 12 h OFF) against continuous EMF (24 h/day) over one week in 7-week-old mice.

Both schedules increased neuronal activity markers, but only the cyclic schedule improved behavior. Whole-brain serotonin was partially restored, regional 5-HT and 5-HIAA increased in several brain regions, and the mice moved toward wild-type behavior in immobility, aggression, and anxiety-related tests. According to the figure legend on page 14, the behavioral assays used n=6 per group, while several molecular and neurochemical measurements were n=3 to n=5. Continuous expression, despite producing a stronger signal on some neuronal activation readouts, did not rescue behavior in the same way. That is a useful reminder that physiology often depends on rhythm, not just amount.

Bottom line

The main takeaway is not simply that EMF “made old mice younger.” It is that the authors may have built a flexible remote-control layer for biology: a way to pulse genes in living tissues with timing that can be biologically meaningful. That has obvious implications for partial reprogramming, disease modeling, and, at least in principle, future therapy development. But it also raises real questions about reproducibility, field scaling, tissue-specific dosimetry, and whether this precision can be maintained in much larger bodies and brains. The paper’s own limitations section explicitly says that larger-animal studies and eventual human work would be needed before serious translation can be discussed.

Discussion Prompt
Which part of this paper seems most important to you: the aging result, the inducible AD model, or the idea that gene therapies may need rhythm and reversibility as much as they need delivery?

Informational only.

Reference: https://www.cell.com/cell/fulltext/S0092-8674(26)00330-2

Summary

• Zeaxanthin is a xanthophyll carotenoid found in foods such as kale, spinach, corn, orange peppers, goji berries, and egg yolks.
• Zeaxanthin selectively accumulates in the macula of the retina, where it helps support normal visual function.
• Zeaxanthin contributes to the body’s antioxidant defenses and helps protect cells from oxidative stress.
• Zeaxanthin helps support and maintain healthy eyes and normal macular function.
• Zeaxanthin helps support healthy cognitive function, including visual processing speed and attention, in adults.

Zeaxanthin Impacts Aging Via

• Inflammaging
• Altered cellular communication

The role of Zeaxanthin in aging and longevity

Zeaxanthin is a xanthophyll carotenoid responsible for the yellow-to-orange pigmentation of several plant foods. Dietary sources include kale, spinach, corn, orange peppers, goji berries, saffron, and egg yolks. Together with lutein, another xanthophyll included in NOVOS Vital, zeaxanthin is one of only two carotenoids that selectively concentrate in the macula of the retina and in the brain, where they form the macular pigment and accumulate in cortical tissue. Zeaxanthin contributes to the body’s antioxidant defenses, helps filter high-energy blue light, and helps support healthy vision, normal macular function, and healthy cognitive performance (including visual processing speed and attention) in adults.

Impact of Zeaxanthin on health

Chronic low-grade inflammation , often termed inflammaging, is recognized as one of the hallmarks of aging (R). Dietary patterns rich in xanthophyll carotenoids, including zeaxanthin, have been associated with a more favorable inflammatory and oxidative profile. In a 4-week controlled feeding trial, adults consuming a high-zeaxanthin plant-based diet showed improvements in biomarkers of low-grade inflammation and oxidative stress (R). Results indicated that increased zeaxanthin intake helps support the body’s antioxidant capacity and is associated with lower levels of oxidative stress markers such as malondialdehyde (MDA).* A comprehensive review further reported that zeaxanthin may help modulate pathways involved in the production of pro-inflammatory mediators, including interleukin-8 (IL-8), IL-6, IL-1α, and endothelial leukocyte adhesion molecule-1 (ELAM-1/E-selectin) (R).

Zeaxanthin and eye health

Vision and ocular function naturally change with age. Common age-related eye conditions studied in the literature include age-related macular degeneration (AMD), cataract, diabetic retinopathy, glaucoma, amblyopia, and presbyopia. Zeaxanthin selectively accumulates in the central retina (the macula), where, together with lutein and meso-zeaxanthin, it forms the macular pigment. In a systematic review of randomized controlled trials, daily supplementation with zeaxanthin and lutein over 3 to 12 months was shown to significantly increase macular pigment optical density (MPOD) in adults (R). MPOD is a validated biomarker used in research to assess macular pigment status. Higher dietary intake of zeaxanthin has been associated with helping maintain healthy vision and normal macular function across the lifespan (R). At the cellular level, in vitro studies suggest that zeaxanthin may help modulate vascular endothelial growth factor (VEGF) signaling in ocular tissues. VEGF is a key regulator of angiogenesis (the formation of new blood vessels, or neovascularization). In retinal cell models, zeaxanthin exposure was associated with reduced VEGF-induced oxidative stress and increased expression of anti-inflammatory markers (R).

Zeaxanthin and brain health

Zeaxanthin and brain health Cognitive performance tends to change gradually with age, and both oxidative stress and chronic low-grade inflammation are recognized contributors to age-related changes in brain function. Xanthophyll carotenoids such as zeaxanthin cross the blood–brain barrier and accumulate in cortical and subcortical tissues, where they contribute to antioxidant defenses and help neutralize free radicals (R). In a 24-month randomized controlled trial, older adults supplemented with a carotenoid blend containing zeaxanthin showed improvements in measures of learning, memory, and attention compared with placebo (R). These findings support a role for zeaxanthin in helping maintain healthy cognitive function in adults. Observational analyses using national health survey data have reported that higher serum zeaxanthin concentrations are associated with a lower likelihood of cognitive decline in adults aged 65 and older (R). Collectively, these data are consistent with a role for zeaxanthin in supporting healthy brain aging.

Zeaxanthin and Lutein

Zeaxanthin and Lutein Lutein is another xanthophyll carotenoid that, alongside zeaxanthin and meso-zeaxanthin, accumulates in the human macula and contributes to the macular pigment that supports normal visual function. Randomized controlled trials have evaluated co-supplementation of lutein and zeaxanthin and found that, taken together, they help support and maintain healthy eyes in adults (R). Clinical research indicates complementary benefits when zeaxanthin is consumed together with lutein. A pooled analysis of eight clinical trials reported that supplementation with lutein and zeaxanthin over 4 to 12 months was associated with improvements in measures of cognitive performance in adults, and that higher circulating levels of these macular pigments were associated with better cognitive outcomes (R). Consistent with these results, an observational analysis examining dietary lutein and zeaxanthin intake in older adults found that higher combined intake was associated with better cognitive performance (R)

If you want more content like this, follow our page 👆

For the full version with images and charts, visit our website where you can explore even more of this content. 👉 NOVOS Labs

If daily habits can influence brain-aging biology, which seems most realistic to sustain: fasting, a Mediterranean-style diet, exercise, or none of the above?

TL;DR
A new review argues that fasting, calorie restriction, high-quality diets, and exercise may influence neurodegeneration-related pathways through overlapping mechanisms, but the strongest mechanistic evidence still comes from animal studies rather than humans.

Quick Takeaways
• This review examines how lifestyle habits may influence mechanisms relevant to Alzheimer’s disease and related neurodegeneration.
• The evidence includes animal studies, human observational studies, pilot trials, and a few larger multidomain clinical trials.
• The core idea is biologically coherent, but we still do not know the exact dose, duration, timing, or combination of habits needed for meaningful protection in humans.

Context

One of the hardest things about Alzheimer’s disease is that by the time symptoms are obvious, the underlying biology has often been changing for years. The classic hallmarks include amyloid-beta plaques, tau tangles, inflammation, synapse loss, and gradual neuronal death. Current drugs can modestly slow decline in some patients, but they do not reverse disease, and they come with limitations, eligibility constraints, and side effects. That leaves a practical question: can everyday behaviors shift the brain toward greater resilience before damage becomes harder to reverse?

This 2026 review in npj Metabolic Health and Disease approaches that question mechanistically. Instead of focusing only on broad epidemiology, it asks how specific lifestyle patterns might affect inflammation, autophagy, mitochondrial function, neurotrophic signaling, amyloid processing, and neuronal survival. The authors organize the evidence around four major strategies: metabolic switching through fasting or ketogenic diets, calorie restriction, high diet quality such as Mediterranean or MIND patterns, and exercise. The summary diagram on page 2 and the mechanistic maps on pages 3, 5, 7, and 9 all reinforce the same central point: these different habits repeatedly converge on a surprisingly similar biology.

Different habits, similar pathways

What makes the review interesting is not the broad claim that “healthy living is good.” It is the more specific argument that several very different habits may influence the same set of brain-relevant pathways.

The recurring targets are inflammation, autophagy, synaptic plasticity, mitochondrial function, and amyloid processing. In simpler terms, that means lifestyle may support the brain by reducing chronic immune activation, improving cellular cleanup, preserving neuronal energy production, supporting synaptic function, and potentially shifting APP processing away from the more harmful amyloidogenic route. The diagrams throughout the paper visualize this almost like a systems map: metabolic switching, calorie restriction, high diet quality, and exercise each feed into lower neuroinflammation and less neuronal loss while promoting neuroprotective mechanisms.

That overlap matters because neurodegeneration is not driven by a single isolated defect. Alzheimer’s is not just an amyloid problem, just an inflammation problem, or just a mitochondrial problem. It is a systems problem. So a lifestyle pattern that modestly improves several pathways at once could, at least in principle, matter more than one narrow intervention. Still, the review is careful here. Most of the strongest mechanistic evidence comes from animal studies, not large human trials with hard clinical endpoints. The biology is compelling, but translation remains the real test.

Fasting and calorie restriction: strong biology, thinner human evidence

The fasting section is probably the most provocative. Intermittent fasting, time-restricted eating, alternate-day fasting, fasting-mimicking diets, and ketogenic diets are grouped under the idea of metabolic switching, meaning a shift from glucose toward fatty acids and ketones such as beta-hydroxybutyrate. In the review’s framework, that switch may increase BDNF, support autophagy, reduce inflammasome activity, improve mitochondrial signaling, and preserve synaptic plasticity. The pathway map on page 3 highlights BDNF, TFEB, AMPK, SIRT1, PGC-1α, and reduced BACE1-related signaling as key nodes in this model.

The preclinical evidence is broad. In mouse models, fasting reduced neuroinflammatory markers, decreased neuronal cell death, improved cognition, altered the gut microbiome, and in some Alzheimer’s models reduced amyloid burden. One example highlighted in the paper is 18:6 time-restricted feeding in APP23 mice, which improved circadian rhythms and sleep, altered expression of AD-related and neuroinflammation-related genes, lowered soluble and insoluble Aβ40 and Aβ42, reduced plaque burden, and improved cognitive performance. Another line of work linked alternate-day fasting to improved synaptic plasticity through SIRT3 signaling. In animal models, the reported effects can be substantial.

But the human evidence is much less mature. The review points to a single-group pilot study of 14-hour nightly fasting in older adults with memory decline that reported improved cognitive screening scores and less insomnia after 8 weeks. It also cites an observational study in older adults with mild cognitive impairment where people who regularly practiced intermittent fasting had better long-term cognitive trajectories over 36 months. There were also multiple sclerosis studies suggesting reduced neuroinflammation and structural brain benefits with intermittent caloric restriction. Useful signals, yes. Definitive evidence for Alzheimer’s prevention or slowed progression, no.

Calorie restriction looks similar. In animal models, 30–40% restriction reduced amyloid plaque burden, lowered microglial activation, improved learning and memory, preserved cerebral glucose metabolism, and activated pathways involving SIRT1, AMPK, autophagy, and alpha-secretase activity. The pathway diagram on page 5 summarizes this well. Some effects were sex-specific in certain mouse models, which is important because it suggests one-size-fits-all prescriptions may fail. In humans, however, direct neurodegeneration evidence remains sparse. The mechanistic story is strong, but the practical prescription is not settled: how much restriction, for whom, for how long, and starting at what age? The review explicitly says those questions remain open.

Diet quality may be more scalable than diet severity

A lot of people are unlikely to sustain alternate-day fasting or substantial calorie restriction. That is why the diet-quality section may be the most relevant in everyday life.

The review focuses on Mediterranean, DASH, and MIND-style eating patterns: minimally processed foods, olive oil, vegetables, nuts, legumes, fish, and lower intake of ultra-processed foods. Mechanistically, these patterns are framed as anti-inflammatory, antioxidant-rich, and potentially supportive of mitochondrial function, autophagy, and healthier amyloid processing. The pathway map on page 7 centers this around BDNF, SIRT1, ATP production, mitochondrial function, reduced oxidative stress, and lower amyloid/tau-related burden. Extra-virgin olive oil gets special attention because several mouse studies found improvements in cognition, inflammatory signaling, oxidative stress, and sometimes amyloid or tau pathology. Olive-derived compounds such as oleocanthal, hydroxytyrosol, and oleuropein aglycone are presented as candidate mediators.

Human data here are mixed. The review notes a randomized trial in cognitively normal adults with a family history of dementia that found no difference in cognition or brain imaging outcomes after 3 years on the MIND diet versus mild calorie restriction. At the same time, observational data from the Framingham Offspring Cohort linked greater adherence to the MIND diet with reduced dementia risk and slower biological aging as measured by DunedinPACE. So the direction is encouraging, but intervention evidence is not uniformly positive.

My read is that diet quality may matter less as a short-term “brain hack” and more as a long-term metabolic environment in which the brain operates. That sounds less dramatic than ketones or fasting-induced autophagy, but it may be more sustainable and scalable.

Exercise may have the strongest overall case

If one intervention comes out of this review looking strongest overall, it may be exercise.

The reason is not just that exercise has plausible mechanisms, but that it has both breadth and a relatively stronger human evidence base. The review emphasizes exerkines such as BDNF, irisin, beta-hydroxybutyrate, and PGC-1α, along with improved autophagy, mitophagy, mitochondrial function, reduced inflammation, and lower amyloid burden in animal models. The pathway map on page 9 highlights these links in detail, including AMPK, SIRT1, TFEB, PINK1/Parkin, BACE1-related signaling, mitochondrial ETC function, and neuronal survival.

In APP/PS1 and related mouse models, treadmill or wheel-running interventions repeatedly improved cognition while reducing plaque load, neuroinflammation, mitochondrial damage, and markers of impaired autophagy. Some studies tied these effects to specific signaling nodes such as AMPK/mTOR, TFEB, PINK1/Parkin, and SIRT1-FOXO pathways.

The human evidence is still not definitive, but it is better than for most dietary strategies discussed here. The review cites a 3-month multimodal exercise intervention in adults with MCI that lowered IL-1β, IL-6, p-tau181, and improved the serum Aβ42/40 ratio. Other studies in older women reported improved cognitive performance alongside increased plasma BDNF after multimodal or high-intensity exercise. There is also observational evidence that better cardiorespiratory fitness is associated with lower risk of becoming amyloid positive. That does not prove exercise prevents dementia, but among the options discussed in the review, it may offer the best combination of plausibility, feasibility, and supporting evidence.

Bottom line

The main message of this review is not that one magical protocol prevents Alzheimer’s. It is that brain aging appears at least partly metabolically and behaviorally responsive. Fasting, calorie restriction, high diet quality, and exercise may all influence pathways linked to inflammation, autophagy, synaptic function, mitochondrial health, and pathological protein burden. But the leap from “works in mice” to “meaningfully changes human disease trajectories” remains incomplete.

Discussion Prompt
Which of these seems most convincing to you: exercise, Mediterranean-style diet, fasting, or a multidomain mix like FINGER and POINTER?

Informational only.

Reference: https://www.nature.com/articles/s44324-026-00101-9

Would you consider a molecule like NMN for fertility support if the evidence looked promising in mice, or is that still too far from human reality?

TL;DR
A new mouse study found that NMN improved ovarian function, egg quality, and embryo development in aged mice, but the benefits were strongly dose-dependent and not proven in humans.

Quick Takeaways

• This paper tested whether NMN can improve ovarian aging and egg quality in older female mice.
• The researchers used both live-animal dosing and embryo culture experiments, then measured follicles, mitochondrial function, oxidative stress, and embryo development.
• The headline result is interesting, but it is still a mouse study with short treatment windows and no human fertility outcomes.

Context

Female reproductive aging is one of the clearest examples of biology running into an energy problem. As ovaries age, egg quality drops, mitochondrial function worsens, reactive oxygen species rise, and the pool of healthy follicles shrinks. That matters not only for fertility, but also for embryo viability and the success of assisted reproduction.

NMN, short for nicotinamide mononucleotide, sits upstream of NAD+, a molecule central to cellular energy metabolism. NAD+ tends to decline with age in many tissues, and that has made NMN a popular candidate in aging research. The basic idea is simple: if aging eggs are partly failing because they are energy-starved and oxidatively stressed, maybe restoring NAD+ could help rescue mitochondrial performance.

That is the question this paper tackled. The authors studied naturally aged female mice, gave them different NMN doses for 10 days, and looked at ovarian reserve, egg quality, and embryo development. They also tested NMN directly in embryo culture media after fertilization. The results are more nuanced than “NMN reverses aging,” but they are genuinely interesting.

What the researchers actually did

The study had two main parts. First, the authors ran an in vivo mouse experiment using young females aged 8 to 12 weeks and older females aged 11 to 12 months. In the dose-finding phase, aged mice received NMN at 200, 500, or 1000 mg/kg/day for 10 days, while young and aged controls got saline. Each group had 8 mice. Based on follicle counts and ovulated oocyte numbers, the authors selected 500 mg/kg/day as the “best” dose for the deeper mechanistic experiments.

They then used larger groups of 33 mice each for young controls, aged controls, and aged mice treated with 500 mg/kg/day NMN. After the same 10-day treatment, they measured ovarian NAD+ and ATP, along with oocyte reactive oxygen species, apoptosis, calcium levels, and mitochondrial membrane potential. They also looked at the expression of SIRT1, PGC-1α, and TOMM20, which are all tied to mitochondrial maintenance and biogenesis.

The second part was an in vitro fertilization and embryo culture experiment. Zygotes from aged mice were cultured with 0, 1, 10, or 100 µM NMN, while embryos from young mice were cultured without NMN as a reference. The main endpoints were fertilization rate, 4/8-cell development, morula formation, and blastocyst formation. That setup let the authors ask two related but different questions: does NMN help the aging ovary in the animal, and can NMN directly improve embryo development in culture?

The main finding: moderate NMN helped, more was not better

This is the part most people will care about. In aged mice, ovarian reserve was lower than in young mice, which is exactly what you would expect. But 500 mg/kg/day NMN increased total follicle number and increased the number of ovulated oocytes after superovulation. By contrast, 200 mg/kg/day did not produce a clear benefit, and 1000 mg/kg/day actually looked worse in some follicle measures, including a significant drop in primary follicles. That is a classic non-linear dose response: too little did not do much, the middle dose helped, and the highest dose may have been counterproductive.

The embryo culture data showed the same pattern. Compared with aged controls, 1 µM NMN improved fertilization and downstream development the most. Fertilization rose from 25.17% in aged controls to 72.94% with 1 µM NMN, while blastocyst formation rose from 21.56% to 68.98%. At 10 µM, the embryos still did better than untreated aged controls, but not as well as 1 µM. At 100 µM, the benefit largely disappeared.

That point matters because supplement discourse often assumes higher doses should work better. This study suggests the opposite may be true in reproductive biology. The authors themselves discuss possible reasons, including transporter saturation, impaired NMN utilization in aged oocytes, and metabolic stress from excessive NAD+-related pathway activation. Those are still hypotheses here, but they fit the data better than a simple “more NMN equals more benefit” model.

Why mitochondria are the center of the story

Mechanistically, the paper is built around mitochondria. The authors found that aged ovaries had lower NAD+ and ATP levels, while NMN raised both. Aged oocytes also showed more ROS, more apoptosis, higher intracellular calcium, and lower mitochondrial membrane potential. NMN shifted all of those in the healthier direction. In plain language, the eggs looked less oxidatively stressed and their mitochondria looked more functional after treatment.

The signaling story is also plausible. NMN increased expression of SIRT1, PGC-1α, and TOMM20 in aged mouse ovarian tissue and oocytes. SIRT1 is an NAD+-dependent deacetylase often linked to stress resistance and mitochondrial regulation. PGC-1α is one of the best-known controllers of mitochondrial biogenesis. TOMM20 is part of the machinery that imports proteins into mitochondria. Together, those markers support the authors’ model that NMN is not just changing one redox measurement, but may be improving mitochondrial quality control more broadly.

That said, this is still a mechanistic association, not a definitive proof chain. The study did not use knockout animals to show that blocking SIRT1 or PGC-1α eliminates the NMN effect. So the pathway is well-motivated, but not fully nailed down.

How convincing is this, really?

As mouse reproductive-aging papers go, this one is fairly solid. It used naturally aged mice rather than an extreme toxin model, looked at multiple endpoints, and showed internal consistency across ovarian reserve, egg stress markers, and embryo development. The dose-response findings also make the study more believable, not less. Biology often behaves like that.

But there are important caveats. First, this was a short intervention: only 10 days of NMN treatment in vivo. That is enough to test a signal, but not enough to answer long-term safety, durability, or whether repeated cycles would still help. Second, mice are not humans, and mouse ovarian aging does not map perfectly onto human fertility decline. Third, the paper measured embryo development up to blastocyst, not live birth or offspring health. Better blastocysts are encouraging, but they are not the same thing as healthy babies.

There is also a practical translation problem. The doses used in mice, especially 500 mg/kg/day, are not something people should casually map onto human supplement habits. And because the paper found that excessive dosing might reduce benefit, self-experimentation becomes even harder to justify.

So my read is this: the study strengthens the case that NAD+ metabolism is involved in reproductive aging, and it suggests NMN is worth further investigation. But it does not justify saying NMN “restores fertility” in women. It shows a promising signal in aged mice, under tightly controlled conditions, with a surprisingly narrow effective window.

The broader implication is less about NMN as a miracle compound and more about reproductive aging as a mitochondrial problem that may be partly modifiable. That is a scientifically interesting idea, and this paper gives it more support. The real question now is whether any of this survives the jump from mouse ovaries to human reproductive medicine.

What do you think is more important here: the encouraging embryo data, or the warning that the dose-response curve may be much less forgiving than supplement culture assumes?

Informational only

Reference: https://link.springer.com/article/10.1007/s43032-026-02092-w

If regular movement helps preserve muscle function with age, could part of that pattern be associated with higher muscle NAD+ levels?

TL;DR

In a human muscle study, older adults had lower muscle NAD+ than younger adults, but exercise-trained older adults looked much closer to the young group than physically impaired peers.

Quick Takeaways

• This study looked at how skeletal muscle metabolism changes with aging, with a special focus on NAD+, a central molecule in cellular energy metabolism.
• Researchers analyzed muscle biopsies from young adults and three groups of older adults: trained, normally active, and physically impaired.
• The main finding was associative rather than causal: lower muscle NAD+ tracked with poorer muscle and mitochondrial health, while exercise-trained older adults had NAD+ levels much closer to those of younger adults.

Context

Aging muscle does not just get smaller or weaker. It also changes metabolically. Mitochondria tend to function less efficiently, insulin sensitivity often declines, and older muscle becomes less adaptable under stress. That matters because skeletal muscle is one of the major tissues supporting mobility, glucose handling, metabolic health, and resilience later in life.

One molecule that repeatedly appears in aging research is NAD+ (nicotinamide adenine dinucleotide). NAD+ helps shuttle electrons for energy production and also serves enzymes involved in DNA repair, stress responses, and mitochondrial regulation. In animal studies, NAD+ often declines with age, and raising it can improve some aspects of physiology. Human evidence has been less consistent. This paper tried to narrow that gap by asking a simple but important question: does NAD+ actually fall in aging human muscle, and if so, is that linked to muscle health in real people? The study suggests yes, with a major caveat: this was a cross-sectional design, so it supports association more than causation.

What the researchers actually did

The study included 52 people total: 12 young adults aged 20–30, plus 40 older adults aged 65–80. The older participants were divided into three groups: 17 exercise-trained older adults, 17 older adults with normal activity levels, and 6 physically impaired older adults. The trained group had performed at least three structured exercise sessions per week for at least one year. The impaired group was defined by a Short Physical Performance Battery score of 9 or below.

This design is more informative than a simple young-versus-old comparison because it allows the researchers to ask whether metabolic differences track not only with age, but also with healthier versus less healthy aging muscle states. That matters, because two older adults of the same age can have very different muscle biology depending on training, function, and physical capacity.

Participants wore activity monitors for 5 days. Young adults and the “normal” older adults both averaged about 10,000 steps per day, which helps reduce the chance that every age effect is merely a fitness effect. The trained older adults averaged roughly 13,000 steps per day and spent more time in high-intensity activity, whereas the impaired group averaged closer to 6,000 steps per day. Researchers then took vastus lateralis muscle biopsies and used mass spectrometry-based metabolomics to profile 137 annotated metabolites. They also assessed mitochondrial respiration, mitochondrial protein abundance, muscle strength, muscle volume, exercise efficiency, and in vivo mitochondrial function.

That combination is one of the strengths of the paper. It was not just a single-metabolite observation; it connected metabolite abundance to actual physiological and functional parameters.

NAD+ stood out

Among the 137 muscle metabolites measured, NAD+ was one of the most clearly depleted in older adults compared with young adults. More importantly, it followed a graded pattern across the groups. The physically impaired older adults had the lowest NAD+ levels. The normally active older adults were also lower than the young group. But the exercise-trained older adults had NAD+ levels much closer to those of young adults. This pattern is visible in Figure 2 on page 3, where NAD+ also shows the strongest association with the study’s “healthy aging” trend.

So the finding was not simply that older age was associated with less NAD+, but that healthier muscle aging profiles were associated with more preserved NAD+.

The paper also found the opposite pattern for oxidative stress-related signals. Ophthalmic acid, a marker associated with oxidative stress, was higher in older adults and highest in the impaired group, while being less elevated in the trained group. Oxiglutathione showed a similar trend. In plain language, lower NAD+ tended to appear in the same biological setting as more oxidative stress and poorer muscle status. That does not prove oxidative stress is causing NAD+ loss, or vice versa, but it does support the idea that they are part of the same aging muscle phenotype.

Why this matters for muscle function

The more useful question is whether this biochemical pattern relates to how muscle actually performs. Here, the answer was yes, at least associationally.

Across the older adults, higher muscle NAD+ was positively associated with mitochondrial respiration. In Figure 4 on page 5, the reported correlation between NAD+ abundance and maximal ADP-stimulated mitochondrial respiration was R = 0.57, P = 0.00014. NAD+ was also positively associated with average daily step count, with R = 0.45, P = 0.0043. In other words, older adults whose muscles contained more NAD+ also tended to have better mitochondrial function and move more in daily life.

The study also identified potentially less favorable signals in the kynurenine pathway. Kynurenic acid was negatively associated with muscle strength, and kynurenine was negatively associated with exercise efficiency in the older adults. That broadens the picture: aging muscle is not just “low NAD+,” but a network shift involving energy metabolism, redox balance, and amino-acid-derived signaling molecules. Still, NAD+ emerged as one of the clearest metabolic markers associated with healthier muscle aging in this dataset.

What this does, and does not, say about boosting NAD+

This is where it is easy to overread the paper. The study supports the idea that muscle NAD+ is relevant to human muscle aging. It does not prove that taking an NAD+ precursor will recreate the physiology seen in the trained older adults.

The authors are careful on this point. They note that changing the NAD+ metabolome in humans does not automatically translate into the full physiological pattern seen with long-term exercise training, which suggests that NAD+ is likely one part of a broader muscle-health picture rather than the whole story. That means NAD+ may be important, but it may not be a single magic lever. Exercise changes blood flow, fiber recruitment, mitochondrial turnover, insulin signaling, inflammation, and many other pathways at once. Preserved NAD+ may be one component of that broader package rather than the whole story.

There are also real limitations. The study was cross-sectional, so reverse causation remains possible: people with healthier muscle biology may maintain higher NAD+, which then helps them stay active, rather than activity itself preserving NAD+. The impaired group was especially small, with only 6 participants, which limits confidence in finer subgroup differences. And muscle biopsies are heterogeneous, meaning the findings could reflect shifts in muscle fiber type or subcellular NAD+ pools rather than a uniform fall in NAD+ everywhere. The authors explicitly raise these issues in the discussion.

So the headline should stay measured: aging human muscle shows lower NAD+, and lower muscle NAD+ is associated with poorer muscle and mitochondrial health. That is a meaningful result, but not yet proof of a supplementation strategy.

Conclusion / Discussion Prompt

What I like about this paper is that it brings NAD+ down from the level of supplement discourse and back into actual human physiology. The most interesting signal here is not that NAD+ is “anti-aging.” It is that exercise-trained older adults seemed to preserve a more youthful-looking muscle metabolic profile, and NAD+ was one of the clearest markers associated with that pattern.

Informational only.

Reference: https://www.nature.com/articles/s43587-022-00174-3